- Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update– click to read
- Catalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option– click to read
- Key Milestone Reached in Catalyst’s Subcutaneous Factor IX Program– click to read
Our most advanced program is focused on the treatment of hemophilia and surgical bleeding using our potent, long acting variants of proteases that promote blood clotting.
*(formerly known as CB 813d)
The Catalyst Advantage
Drug candidates for severe medical conditions
Learn more about the medicines we are developing.
Addressing diseases with unmet medical needs
Share our passion about treating disease.
We have an experienced and passionate team
Learn more about the Catalyst team and mission/culture.